Effect of anti-diabetic drugs on central macular thickness in patients with type 2 diabetes mellitus
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 6, Pages 643-647
AbstractAim: To compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and healthy subjects.
Material & Methods: This is a prospective study, carried out on 92 patients. The patients were divided in to two groups: study group included 50 patients and control group comprised of 42 patients.
Results: The mean HbA1c level was 8.68 ± 2.39% in the study group and 5.10 ± 0.76% in the control group. The mean level of HbA1c was statistically higher in the study group than in the control group (Table 1, P = 0.001). Fasting plasma glucose level was statistically higher in the study group than in the control group (P= 0.001).
Conclusion: Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects
- Article View: 20
- PDF Download: 26